The role of the CD44/ezrin complex in cancer metastasis

Critical Reviews in Oncology/Hematology

Volumn 46, Issue 2, 2003, Pages 165-186

  Martin, Tracey A ^a   Harrison, Gregory ^a   Mansel, Robert E ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cancer metastasis; CD44; Cell adhesion; Ezrin; Hyaluranon

Indexed keywords

CANCER GROWTH FACTOR; EZRIN; GAMMA INTERFERON; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 8; SCATTER FACTOR; TUMOR NECROSIS FACTOR;

BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CLINICAL STUDY; COLORECTAL CANCER; ENDOTHELIUM; ESOPHAGUS CANCER; GYNECOLOGIC CANCER; HUMAN; METASTASIS; MOLECULE; MOUTH CANCER; PROSTATE CANCER; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; STOMACH CANCER; TUMOR GROWTH;

EID: 0037403773     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00172-5     Document Type: Review

References (193)

1. Brooks P.C. Cell adhesion molecules in angiogenesis. Can. Met. Rev. 15:1996;187-194.
2. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 267:(16):1992;10931-10934.
3. Folkman J. Fighting cancer by attacking its blood supply, Sci. Am. 1996;275(3):150-4.
4. Ono M., Torisu H., Fukushi J., Nishie A., Kuwano M. Biological implications of macrophage infiltration in human tumour angiogenesis. Can. Chem. Pharm. 43:1999;S69-S71.
5. Jiang W.G., Hiscox S., Singhrao S.K., et al. Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor/scatter factor. Biochem. Biophys. Res. Commun. 217:(3):1995;1062-1069.
6. Hart I.R., Goode N.T., Wilson R.E. Molecular aspects of the metastatic cascade. Biochim. Biophys. Acta. 989:(1):1989;65-84.
7. Bretscher A., Reczek D., Berryman M. Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J. Cell Sci. 110:(24):1997;3011-3018.
8. Arpin M., Algrain M., Louvard D. Membrane-actin microfilament connections: an increasing diversity of players related to band 4.1. Curr. Opin. Cell Biol. 6:(1):1994;136-141.
9. Yonemura S., Tsukita S., Tsukita S. Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J. Cell Biol. 145:(7):1999;1497-1509.
10. Sainio M., Zhao F., Heiska L., et al. Neurofibromatosis 2 tumour suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J. Cell Sci. 110:(Pt 18):1997;2249-2260.
11. Screaton G.R., Bell M.V., Jackson D.G., Cornelis F.B., Gerth U., Bell J.I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA. 89:(24):1992;12160-12164.
12. Brown T.A., Bouchard T., St John T., Wayner E., Carter W.G. Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J. Cell Biol. 113:(1):1991;207-221.
13. Jalkanen S., Jalkanen M., Bargatze R., Tammi M., Butcher E.C. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J. Immunol. 141:(5):1988;1615-1623.
14. Lesley J., Hyman R., Kincade P.W. CD44 and its interaction with extracellular matrix. Adv. Immunol. 54:1993;271-335.
15. Lokeshwar V.B., Iida N., Bourguignon L.Y. The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J. Biol. Chem. 271:(39):1996;23853-23864.
16. Bretscher A. Microfilament organization in the cytoskeleton of the intestinal brush border. Cell Muscle Motil. 4:1983;239-268.
17. Tran Y.K., Bogler O., Gorse K.M., Wieland I., Green M.R., Newsham I.F. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 59:(1):1999;35-43.
18. Vaheri A., Carpen O., Heiska L., et al. The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr. Opin. Cell Biol. 9:(5):1997;659-666.
19. Crepaldi T., Gautreau A., Comoglio P.M., Louvard D., Arpin M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 138:(2):1997;423-434.
20. Hoover K.B., Bryant P.J. The genetics of the protein 4.1 family: organizers of the membrane and cytoskeleton. Curr. Opin. Cell Biol. 12:(2):2000;229-234.
21. Granes F., Urena J.M., Rocamora N., Vilaro S. Ezrin links syndecan-2 to the cytoskeleton. J. Cell Sci. 7:2000;1267-1276.
22. Gronholm M., Sainio M., Zhao F., Heiska L., Vaheri A., Carpen O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J. Cell Sci. 112:(6):1999;895-904.
23. Tsukita S., Yonemura S., Tsukita S. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem. Sci. 2:1997;53-58.
24. Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family, Curr. Opin. Cell Biol. 1999;11(1):109-16.
25. Ingraffea J., Reczek D., Bretscher A. Distinct cell type-specific expression of scaffolding proteins EBP50 and E3KARP: EBP50 is generally expressed with ezrin in specific epithelia, whereas E3KARP is not. Eur. J. Cell Biol. 81:(2):2002;61-68.
26. Fanning A.S., Anderson J.M. Protein modules as organizers of membrane structure. Curr. Opin. Cell Biol. 11:(4):1999;432-439.
27. Skoudy A., Nhieu G.T., Mantis N., et al. A functional role for ezrin during Shigella flexneri entry into epithelial cells. J. Cell Sci. 112:(13):1999;2059-2068.
28. Heiska L., Alfthan K., Gronholm M., Vilja P., Vaheri A., Carpen O. Association of ezrin with intercellular adhesion molecule-1 and -2 (ICAM-1 and ICAM-2). Regulation by phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem. 273:(34):1998;21893-21900.
29. Serrador J.M., Nieto M., Alonso-Lebrero J.L., et al. CD43 interacts with moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell contacts. Blood. 91:(12):1998;4632-4644.
30. Akisawa N., Nishimori I., Iwamura T., Onishi S., Hollingsworth M.A. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem. Biophys. Res. Commun. 258:(2):1999;395-400.
31. Welsh C.F., Zhu D., Bourguignon L.Y. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J. Cell. Physiol. 164:(3):1995;605-612.
32. Bourguignon L.Y., Iida N., Welsh C.F., Zhu D., Krongrad A., Pasquale D. Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. J. Neurooncol. 26:(3):1995;201-208.
33. Bourguignon L.Y., Zhu H., Chu A., Iida N., Zhang L., Hung M.C. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J. Biol. Chem. 272:(44):1997;27913-27918.
34. Zhu D., Bourguignon L. Overexpression of CD44 in pl85(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion. Oncogene. 12:(11):1996;2309-2314.
35. Goldstein L.A., Zhou D.F., Picker L.J., et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell. 56:(6):1989;1063-1072.
36. Alho A.M., Underhill C.B. The hyaluronate receptor is preferentially expressed on proliferating epithelial cells. J. Cell Biol. 108:(4):1989;1557-1565.
37. Stamenkovic I., Amiot M., Pesando J.M., Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell. 56:(6):1989;1057-1062.
38. Dougherty G.J., Landorp P.M., Cooper D.L., Humphries R.K. Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte 'homing' receptor expressed by hemopoietic cells. J. Exp. Med. 174:(1):1991;1-5.
39. Picker L.J., Nakache M., Butcher E.C. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J. Cell Biol. 109:(2):1989;927-937.
40. Liao H.X., Levesque M.C., Patton K., et al. Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies. J. Immunol. 151:(11):1993;6490-6499.
41. Hiscox S., Jiang W.G. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J. Cell Sci. 112:(18):1999;3081-3090.
42. Andreoli C., Martin M., Le Borgne R., Reggio H., Mangeat P. Ezrin has properties to self-associate at the plasma membrane. J. Cell Sci. 107:(9):1994;2509-2521.
43. Yao X., Cheng L., Forte J.G. Biochemical characterization of ezrin-actin interaction. J. Biol. Chem. 271:(12):1996;7224-7229.
44. Shuster C.B., Herman I.M. Indirect association of ezrin with F-actin: isoform specificity and calcium sensitivity. J. Cell Biol. 128:(5):1995;837-848.
45. Alonso-Lebrero J.L., Serrador J.M., Dominguez-Jimenez C., et al. Polarization and interaction of adhesion molecules P-selectin glycoprotein ligand 1 and intercellular adhesion molecule 3 with moesin and ezrin in myeloid cells. Blood. 95:(7):2000;2413-2419.
46. O'Toole E.A., Marinkovich M.P., Peavey C.L., et al. Hypoxia increases human keratinocyte motility on connective tissue. J. Clin. Invest. 100:(11):1997;2881-2891.
47. Helander T.S., Carpen O., Turunen O., Kovanen P.E., Vaheri A., Timonen T. ICAM-2 redistributed by ezrin as a target for killer cells. Nature. 382:(6588):1996;265-268.
48. Kaul S.C., Kawai R., Nomura H., Mitsui Y., Reddel R.R., Wadhwa R. Identification of a 55-kDa ezrin-related protein that induces cytoskeletal changes and localizes to the nucleolus. Exp. Cell Res. 250:(1):1999;51-61.
49. Kryworuchko M., Gee K., Diaz-Mitoma F., Kumar A. Regulation of CD44-hyaluronan interactions in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid B cells by PMA and interleukin-4. Cell. Immunol. 194:(1):1999;54-66.
50. Trejdosiewicz L.K., Morton R., Yang Y., Banks R.E., Selby P.J., Southgate J. Interleukins 4 and 13 upregulate expression of cd44 in human colonic epithelial cell lines. Cytokine. 10:(10):1998;756-765.
51. Zittermann S.I., Achino B.I., Agriello E.E., Halperin N., Ramhorst R.E., Fainboim L. Modulation of CD44 in acute lymphoblastic leukemia identifies functional and phenotypic differences of human B cell precursors. Eur. J. Haematol. 66:(6):2001;377-382.
52. Cichy J., Pure E. Oncostatin M and transforming growth factor-beta 1 induce post-translational modification and hyaluronan binding to CD44 in lung-derived epithelial tumor cells. J. Biol. Chem. 275:(24):2000;18061-18069.
53. Ringel J., Jesnowski R., Schmidt C., et al. CD44 in normal human pancreas and pancreatic carcinoma cell lines. Teratog. Carcinog. Mutag. 21:(1):2001;97-106.
54. Wimmenauer S., Steiert A., Wolff-Vorbeck G., et al. Influence of cytokines on the expression of fas ligand and CD44 splice variants in colon carcinoma cells. Tumour Biol. 20:(6):1999;294-303.
55. Barshishat M., Ariel A., Cahalon L., Chowers Y., Lider O., Schwartz B. TNFalpha and IL-8 regulate the expression and function of CD44 variant proteins in human colon carcinoma cells. Clin. Exp. Metastasis. 19:(4):2002;327-337.
56. Koyama T., Yashiro M., Inoue T., Nishimura S., Hirakawa Y.S., Chung K. TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int. J. Oncol. 16:(2):2000;355-362.
57. Monaghan M., Mulligan K.A., Gillespie H., et al. Epidermal growth factor up-regulates CD44-dependent astrocytoma invasion in vitro. J. Pathol. 192:(4):2000;519-525.
58. Pearson M.A., Reczek D., Bretscher A., Karplus P.A. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 101:(3):2000;259-270.
59. Gary R., Bretscher A. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol. Biol. Cell. 6:(8):1995;1061-1075.
60. Krieg J., Hunter T. Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J. Biol. Chem. 267:(27):1992;19258-19265.
61. Dransfield D.T., Bradford A.J., Smith J., et al. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J. 16:(1):1997;35-43.
62. Hirao M., Sato N., Kondo T., et al. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J. Cell Biol. 135:(1):1996;37-51.
63. Yonemura S., Hirao M., Doi Y., et al. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43 and ICAM-2. J. Cell Biol. 140:(4):1998;885-895.
64. Niggli V., Andreoli C., Roy C., Mangeat P. Identification of a phosphatidylinositol-4,5-bisphosphate-binding domain in the N-terminal region of ezrin. FEBS Lett. 376:(3):1995;172-176.
65. Tsukita S., Oishi K., Sato N., Sagara J., Kawai A., Tsukita S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol. 126:(2):1994;391-401.
66. Liu D., Liu T., Sy M.S. Identification of two regions in the cytoplasmic domain of CD44 through which PMA, calcium, and foskolin differentially regulate the binding of CD44 to hyaluronic acid. Cell. Immunol. 190:(2):1998;132-140.
67. West D.C., Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp. Cell Res. 183:(1):1989;179-196.
68. Lokeshwar V.B., Bourguignon L.Y. Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J. Biol. Chem. 266:(27):1991;17983-17989.
69. Lokeshwar V.B., Fregien N., Bourguignon L.Y. Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function. J. Cell. Biol. 126:(4):1994;1099-1109.
70. Cao L., Yoshino T., Kawasaki N., Yanai H., Kawahara K., Kondo E., et al. Binding of human leukocytes to fibronectin is augmented by an anti-CD44 mAb (TL-1) and blocked by another anti-CD44 mAb (Hermes-3) but not by anti-VLA-4/VLA-5 mAbs. Immunobiology. 196:(5):1996;504-512.
71. Bourguignon L.Y., Jin H. Identification of the ankyrin-binding domain of the mouse T-lymphoma cell inositol 1,4,5-trisphosphate (IP3) receptor and its role in the regulation of IP3-mediated internal Ca2+ release. J. Biol. Chem. 270:(13):1995;7257-7260.
72. Miyake K., Medina K.L., Hayashi S., Ono S., Hamaoka T., Kincade P.W. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J. Exp. Med. 171:(2):1990;477-488.
73. Laurent T.C., Fraser J.R. Hyaluronan. FASEB J. 6:(7):1992;2397-2404.
74. Lacy B.E., Underhill C.B. The hyaluronate receptor is associated with actin filaments. J. Cell Biol. 105:(3):1987;1395-1404.
75. Kalomiris E.L., Bourguignon L.Y. Mouse T lymphoma cells contain a transmembrane glycoprotein (GP85) that binds ankyrin. J. Cell Biol. 106:(2):1988;319-327.
76. Bourguignon L.Y., Kalomiris E.L., Lokeshwar V.B. Acylation of the lymphoma transmembrane glycoprotein, GP85, may be required for GP85-ankyrin interaction. J. Biol. Chem. 266:(18):1991;11761-11765.
77. Bourguignon L.Y., Lokeshwar V.B., He J., Chen X., Bourguignon G.J. A CD44-like endothelial cell transmembrane glycoprotein (GP116) interacts with extracellular matrix and ankyrin. Mol. Cell. Biol. 12:(10):1992;4464-4471.
78. Bourguignon L.Y., Lokeshwar V.B., Chen X., Kerrick W.G. Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J. Immunol. 151:(12):1993;6634-6644.
79. Lokeshwar V.B., Bourguignon L.Y. Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J. Biol. Chem. 266:(27):1991;17983-17989.
80. Lokeshwar V.B., Bourguignon L.Y. Tyrosine phosphatase activity of lymphoma CD45 (GP180) is regulated by a direct interaction with the cytoskeleton. J. Biol. Chem. 267:(30):1992;21551-21557.
81. Kalomiris E.L., Bourguignon L.Y. Lymphoma protein kinase C is associated with the transmembrane glycoprotein, GP85, and may function in GP85-ankyrin binding. J. Biol. Chem. 264:(14):1989;8113-8119.
82. Galluzzo E., Albi N., Fiorucci S., et al. Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells. Eur. J. Immunol. 25:(10):1995;2932-2939.
83. Toole B.P. Hyaluronan and its binding proteins, the hyaladherins. Curr. Opin. Cell Biol. 2:(5):1990;839-844.
84. Knudson C.B., Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J. 7:(13):1993;1233-1241.
85. Underhill C.B. The interaction of hyaluronate with the cell surface: the hyaluronate receptor and the core protein. Ciba Found Symp. 143:1989;87-99.
86. Tarone G., Ferracini R., Galetto G., Comoglio P. A cell surface integral membrane glycoprotein of 85 000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton. J. Cell Biol. 99:(2):1984;512-519.
87. Lokeshwar V.B., Bourguignon L.Y. The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction. J. Biol. Chem. 267:(31):1992;22073.
88. Culty M., Miyake K., Kincade P.W., Sikorski E., Butcher E.C., Underhill C., et al. The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J. Cell Biol. 111:(6 Pt 1):1990;2765-2774.
89. Toyama-Sorimachi N., Miyasaka M. A novel ligand for CD44 is sulfated proteoglycan. Int. Immunol. 6:(4):1994;655-660.
90. Carter W.G., Wayner E.A. Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J. Biol. Chem. 263:(9):1988;4193-4201.
91. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 61:(7):1990;1303-1313.
92. Sy M.S., Guo Y.J., Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J. Exp. Med. 174:(4):1991;859-866.
93. Faassen A.E., Schrager J.A., Klein D.J., Oegema T.R., Couchman J.R., McCarthy J.B. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J. Cell Biol. 116:(2):1992;521-531.
94. Jalkanen S., Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J. Cell Biol. 116:(3):1992;817-825.
95. Ishii S., Ford R., Thomas P., Nachman A., Steele G. Jr, Jessup J.M. CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. Surg. Oncol. 2:(4):1993;255-264.
96. Bartolazzi A., Peach R., Aruffo A., Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 180:(1):1994;53-66.
97. Romaris M., Bassols A., David G. Effect of transforming growth factor-beta 1 and basic fibroblast growth factor on the expression of cell surface proteoglycans in human lung fibroblasts. Enhanced glycanation and fibronectin-binding of CD44 proteoglycan, and down-regulation of glypican. Biochem. J. 310:(1):1995;73-81.
98. Toyama-Sorimachi N., Miyasaka M. A sulfated proteoglycan as a novel ligand for CD44. J. Dermatol. 21:(11):1994;795-801.
99. Toyama-Sorimachi N., Sorimachi H., Tobita Y., Kitamura F., Yagita H., Suzuki K., et al. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J. Biol. Chem. 270:(13):1995;7437-7444.
100. Naujokas M.F., Morin M., Anderson M.S., Peterson M., Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell. 74:(2):1993;257-268.
101. Pawlak G., Helfman D.M. Cytoskeletal changes in cell transformation and tumourigenesis. Curr. Opin. Genet. Dev. 11:(1):2000;41-47.
102. Yonemura S., Matsui T., Tsukita S., Tsukita S. Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J. Cell Sci. 115:(12):2002;2569-2580.
103. Legras S., Gunthert U., Stauder R., Curt F., Oliferenko S., Kluin-Nelemans H.C., et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood. 91:(9):1998;3401-3413.
104. Wielenga V.J., van der Neut R., Offerhaus G.J., Pals S.T. CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv. Cancer Res. 77:2000;169-187.
105. Castella E.M., Ariza A., Pellicer I., Fernandez-Vasalo A., Ojanguren I. Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma. J. Clin. Pathol. 51:(2):1998;134-137.
106. Xin Y., Grace A., Gallagher M.M., Curran B.T., Leader M.B., Kay E.W. CD44V6 in gastric carcinoma: a marker of tumor progression. Appl. Immunohistochem. Mol. Morphol. 9:(2):2001;138-142.
107. Endo K., Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J. Hepatol. 32:(1):2000;78-84.
108. Tran T.A., Kallakury B.V., Sheehan C.E., Ross J.S. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum. Pathol. 28:(7):1997;809-814.
109. Miyoshi T., Kondo K., Hino N., Uyama T., Monden Y. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin. Cancer Res. 3:(8):1997;1289-1297.
110. Dome B., Somlai B., Ladanyi A., Fazekas K., Zoller M., Timar J. Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma. Virchows Arch. 439:(5):2001;628-635.
111. Stauder R., Van Driel M., Schwarzler C., Thaler J., Lokhorst H.M., Kreuser E.D., et al. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood. 88:(8):1996;3101-3108.
112. Beham-Schmid C., Heider K.H., Hoefler G., Zatloukal K. Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse. J. Pathol. 186:(4):1998;383-389.
113. Stauder R., Eisterer W., Thaler J., Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood. 85:(10):1995;2885-2899.
114. Ristamaki R., Joensuu H., Soderstrom K.O., Jalkanen S. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis. J. Pathol. 176:(3):1995;259-267.
115. Gotoda T., Matsumura Y., Kondo H., Ono H., Kanamoto A., Kato H., et al. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut. 46:(1):2000;14-19.
116. Fonseca I., Pereira T., Rosa-Santos J., Soares J. Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: a correlation with histological grade, pattern of stromal invasion, and cell differentiation. J. Surg. Oncol. 76:(2):2001;115-120.
117. Sato S., Miyauchi M., Takekoshi T., Zhao M., Kudo Y., Ogawa I., et al. Reduced expression of CD44 variant 9 is related to lymph node metastasis and poor survival in squamous cell carcinoma of tongue. Oral Oncol. 36:(6):2000;545-549.
118. Gansauge F., Gansauge S., Zobywalski A., Scharnweber C., Link K.H., Nussler A.K., et al. Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res. 55:(23):1995;5499-5503.
119. Gotoda T., Matsumura Y., Kondo H., Saitoh D., Shimada Y., Kosuge T., et al. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn. J. Cancer Res. 89:(10):1998;1033-1040.
120. Bohm J.P., Niskanen L.K., Pirinen R.T., Kiraly K., Kellokoski J.K., Moisio K.I., et al. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. J. Pathol. 192:(3):2000;321-327.
121. Iczkowski K.A., Shanks J.H., Bostwick D.G. Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma. Histopathology. 32:(4):1998;322-327.
122. Lipponen P., Aaltoma S., Kosma V.M., Ala-Opas M., Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J. Pathol. 186:(2):1998;157-164.
123. Dall P., Hekele A., Ikenberg H., Goppinger A., Bauknecht T., Pfleiderer A., et al. Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis. Int. J. Cancer. 69:(2):1996;79-85.
124. Ayhan A., Baykal C., Al A. Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma. Gynecol. Oncol. 83:(3):2001;567-569.
125. Menager C., Vassy J., Doliger C., Legrand Y., Karniguian A. Subcellular localization of RhoA and ezrin at membrane ruffles of human endothelial cells: differential role of collagen and fibronectin. Exp. Cell Res. 249:(2):1999;221-230.
126. Defacque H., Egeberg M., Habermann A., et al. Involvement of ezrin/moesin in de novo actin assembly on phagosomal membranes. EMBO J. 19:(2):2000;199-212.
127. Parlato S., Giammarioli A.M., Logozzi M., et al. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19:(19):2000;5123-5134.
128. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:(1):1991;13-24.
129. Rudy W., Hofmann M., Schwartz-Albiez R., Zoller M., Heider K.H., Ponta H., et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res. 53:(6):1993;1262-1268.
130. Dall P., Heider K.H., Hekele A., von Minckwitz G., Kaufmann M., Ponta H., et al. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res. 54:(13):1994;3337-3341.
131. Iida N., Bourguignon L.Y. New CD44 splice variants associated with human breast cancers. J. Cell. Physiol. 162:(1):1995;127-133.
132. Button E., Shapland C., Lawson D. Actin, its associated proteins and metastasis. Cell Motil. Cytoskeleton. 30:(4):1995;247-251.
133. Lamb R.F., Ozanne B.W., Roy C., et al. Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal and transformed fibroblasts. Curr. Biol. 7:(9):1997;682-688.
134. Ohtani K., Sakamoto H., Rutherford T., Chen Z., Satoh K., Naftolin F. Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett. 147:(1-2):1999;31-38.
135. Kaul S.C., Mitsui Y., Komatsu Y., Reddel R.R., Wadhwa R. A highly expressed 81 kDa protein in immortalized mouse fibroblast: its proliferative function and identity with ezrin. Oncogene. 13:(6):1996;1231-1237.
136. Lamb R.F., Roy C., Diefenbach T.J., et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat. Cell Biol. 2:(5):2000;281-287.
137. Tran Y.K., Bogler O., Gorse K.M., Wieland I., Green M.R., Newsham I.F. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 59:1999;35-43.
138. Bohling T., Turunen O., Jaaskelainen J., et al. Ezrin expression in stromal cells of capillary hemangioblastoma. An immunohistochemical survey of brain tumours. Am. J. Pathol. 148:(2):1996;367-373.
139. Helander T.S., Carpen O., Turunen O., Kovanen P.E., Vaheri A., Timonen T. ICAM-2 redistributed by ezrin as a target for killer cells. Nature. 382:(6588):1996;265-268.
140. Setala L., Lipponen P., Tammi R., et al. Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer. Histopathology. 38:2001;13-20.
141. Ichikawa T., Masumoto J., Kaneko M., Saida T., Sagara J., Taniguchi S. Expression of moesin and its associated molecule CD44 in epithelial skin tumors. J. Cutaneous Pathol. 25:(5):1998;237-243.
142. Ichikawa T., Masumoto J., Kaneko M., Saida T., Sagara J., Taniguchi S. Moesin and CD44 expression in cutaneous melanocytic tumours. Br. J. Dermatol. 138:(5):1998;763-768.
143. Lara-Pezzi E., Serrador J.M., Montoya M.C., et al. The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology. 33:(5):2001;1270-1281.
144. Herrlich P., Morrison H., Sleeman J., et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann. New York Acad. Sci. J910:2000;106-118. Discussion 118-120.
145. Zohar R., Suzuki N., Suzuki K., et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell. Physiol. 184:2000;118-130.
146. Coppola D., Hyacinthe M., Fu L., et al. CD44V6 expression in human colorectal carcinoma. Hum. Pathol. 29:1998;627-635.
147. Furuta K., Zahurak M., Goodman S.N., Hamilton S.R., August J.T. CD44 expression in the stromal matrix of colorectal cancer: association with prognosis. Clin. Cancer Res. 4:1998;21-29.
148. Jungling B., Menges M., Goebel R., et al. Expression of CD44v6 has no prognostic value in patients with colorectal cancer. Z. Gastroenterol. 40:2002;229-233.
149. Sokmen S., Lebe B., Sarioglu S., et al. Prognostic value of CD44 expression in colorectal carcinomas. Anticancer Res. 21:2001;4121-4126.
150. Asao T., Nakamura J., Shitara Y., et al. Loss of standard type of CD44 expression in invaded area as a good indicator of lymph-node metastasis in colorectal carcinoma. Dis. Colon Rectum. 43:2000;1250-1254.
151. Hefler L.A., Concin N., Mincham D., et al. The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma - a multicenter study. Cancer. 94:2002;125-130.
152. Rodriguez-Rodriguez L., Sancho-Torres I., Gibbon D.G., Watelet L.F.M., Mesonero C. CD44-9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva. J. Soc. Gynecol. Invest. 7:2000;70-75.
153. Rodriguez-Rodriguez L., Sancho-Torres I., Watelet L.M., Gibbon D.G., Comerci J.T., Mesonero C. Prognostic value of CD44 expression in invasive squamous cell carcinoma of the vulva. Gynecol. Oncol. 75:1999;34-40.
154. Rodriguez-Rodriguez L., Sancho-Torres I., Leakey P., et al. CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol. Oncol. 71:1998;223-229.
155. Kayastha S., Freedman A.N., Piver M.S., Mukkamalla J., Romero-Guittierez M., Werness B.A. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin. Cancer Res. 5:1999;1073-1076.
156. Sancho-Torres I., Mesonero C., Watelet J.L.M., Gibbon D., Rodriguez-Rodriguez L. Clear cell carcinoma of the ovary: characterization of its CD44 isoform repertoire. Gynecol. Oncol. 79:2000;187-195.
157. Charpin C., Garcia S., Bouvier C., et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum. Pathol. 28:1997;289-296.
158. Tempfer C., Losch A., Heinzl H., et al. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur. J. Cancer. 32A:1996;2023-2025.
159. Dall P., Heider K.H., Sinn H.P., et al. Comparison of immunohistochemistry and RT-PCR for detection of CD44V-expression, a new prognostic factor in human breast-cancer. Int. J. Cancer. 60:1995;471-477.
160. Setala L., Lipponen P., Tammi R., et al. Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer. Histopathology. 38:2001;13-20.
161. Takahashi S., Kimoto N., Orita S., Cui L., Sakakibara M., Shirai T. Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett. 129:1998;97-102.
162. Fabricius E.M., Guschmann M., Wildner G.P., Langford A., Hell B., Bier J. Divergent immunohistochemical E48 and CD44-V6 antigen expression patterns between lymph node metastases and primary squamous cell carcinomas in the head and neck region. Cancer J. 11:1998;153-159.
163. Carinci F., Stabellini G., Calvitti M., et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J. Craniofac. Surg. 13:2002;85-89.
164. Turner J.R., Torres C.M., Wang H.H., et al. Preoperative chemoradiotherapy alters the expression and prognostic significance of adhesion molecules in Barrett's-associated adenocarcinoma. Hum. Pathol. 31:2000;347-353.
165. Bottger T.G., Youssef V., Dutkowski P., Maschek H., Brenner W., Junginger T. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis. Cancer. 83:1998;1074-1080.
166. Yokoyama Y., Hiyama E., Murakami Y., Matsuura Y., Yokoyama T. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma. Cancer. 86:1999;1691-1699.
167. Okamoto I., Kawano Y., Matsumoto M., et al. Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins. J. Biol. Chem. 274:1999;25525-25534.
168. Kopp R., Classen S., Wolf H., et al. Predictive relevance of soluble
169. Van Hal N.L.W., Van Dongen G.A.M.S., Ten Brink C.B.M., et al. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin. Cancer Res. 5:1999;3534-3541.
170. Kittl E.M., Ruckser R., Selleny S., et al. Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients. Exp. Clin. Immunogenet. 14:1997;264-272.
171. Ropponen K., Tammi M., Parkkinen J., et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 58:1998;342-347.
172. Auvinen P., Tammi R., Parkkinen J., et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 156:2000;529-536.
173. Bohm J., Niskanen L., Tammi R., et al. Hyaluronan expression in differentiated thyroid carcinoma. J. Pathol. 196:2002;180-185.
174. Lipponen P., Aaltomaa S., Tammi R., Tammi M., Agren U., Kosma V.M. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur. J. Cancer. 37:2001;849-856.
175. Furuta K., Zahurak M., Goodman S.N., Hamilton S.R., August J.T. CD44 expression in the stromal matrix of colorectal cancer: association with prognosis. Clin. Cancer Res. 4:(1):1998;21-29.
176. Jiang W.G., Hiscox S., Singhrao S.K., et al. Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor (HGF/SF). Biochem. Biophys. Res. Commun. 217:1995;1062-1069.
177. Ohtani K., Sakamoto H., Rutherford T., et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett. 179:2002;79-86.
178. Chen Z.C., Fadiel A., Feng Y.J., Ohtani K., Rutherford T., Naftolin F. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1 alpha and epidermal growth factor. Cancer. 92:2001;3068-3075.
179. Stemmer-Rachamimov A.O., Wiederhold T., Nielsen G.P., et al. NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am. J. Pathol. 158:2001;57-62.
180. Tokunou M., Niki T., Saitoh Y., Imamura H., Sakamoto M., Hirohashi S. Altered expression of the ERM proteins in lung adenocarcinoma. Lab. Invest. 80:2000;1643-1650.
181. Carmeci C., Thompson D.A., Kuang W.W., Lightdale N., Furthmayr H., Weigel R.J. Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype. Surgery. 124:1998;211-217.
182. Bianchi A.B., Hara T., Ramesh V., et al. Mutations in transcript isoforms of the neurofibromatosis-2 gene in multiple human tumor types. Nat. Genet. 6:1994;185-192.
183. McClatchey A.I., Saotome I., Mercer K., et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12:1998;1121-1133.
184. Weber G.F. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta. 1552:(2):2001;61-85.
185. Weber G.F., Ashkar S., Cantor H. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc. Assoc. Am. Physicians. 109:(1):1997;1-9.
186. Paradis V., Eschwege P., Loric S., et al. De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J. Clin. Pathol. 51:1998;798-802.
187. Kopp R., Classen S., Wolf H., Gholam P., Possinger K., Wilmanns W. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res. 21:(4B):2001;2995-3000.
188. Costa S., Terzano P., Bovicelli A., et al. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol. Oncol. 80:2001;67-73.
189. Ristamaki R., Joensuu H., Lappalainen K., Teerenhovi L., Jalkanen S. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood. 90:1997;4039-4045.
190. Verkaik N.S., van Steenbrugge G.J., van Weerden W.M., Bussemakers M.J., van der Kwast T.H. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab. Invest. 80:2000;1291-1298.
191. Kito H., Suzuki H., Ichikawa T., et al. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate. 49:2001;110-115.
192. Aaltomaa S., Lipponen P., Ala-Opas M., Kosma V.M. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur. Urol. 39:2001;138-144.
193. Ross J.S., Sheehan C.E., Williams S.S., Malfetano J.H., Szyfelbein W.M., Kallakury B.V.S. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am. J. Clin. Pathol. 116:2001;122-128.